Top
Main

All outcomes

Feedback
Home
Top   Main   All Outcomes
Loading...
Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) N-acetylcys.. (meta)
Bromhexine (meta) Nigella Sativa (meta)
Budesonide (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Povidone-Iod.. (meta)
Conv. Plasma (meta) Probiotics (meta)
Curcumin (meta) Proxalutamide (meta)
Ensovibep (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychlor.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
N-acetylcys..
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc
Supplementary Data — Colchicine for COVID-19: real-time meta analysis of 13 studies
Covid Analysis, January 18, 2022, DRAFT
https://c19colchicine.com/meta.html
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Deftereos (RCT) 77% 0.23 [0.03-1.97] death 1/55 4/50 Improvement, RR [CI] Treatment Control Deftereos (RCT) 82% 0.18 [0.02-1.50] ventilation 1/55 5/50 Deftereos (RCT) 87% 0.13 [0.01-0.97] progression 1/55 7/50 Lopes (DB RCT) 80% 0.20 [0.01-4.03] death 0/36 2/36 Lopes (DB RCT) 50% 0.50 [0.10-2.56] ICU 2/36 4/36 Brunetti (PSM) 73% 0.27 [0.08-0.89] death 3/33 11/33 Brunetti (PSM) 73% 0.27 [0.08-0.89] no disch. 3/33 11/33 Scarsi 85% 0.15 [0.06-0.37] death 122 (n) 140 (n) Salehzadeh (RCT) 23% 0.77 [0.66-0.90] hosp. time 50 (n) 50 (n) Pinzón 35% 0.65 [0.34-1.21] death 14/145 23/156 Sandhu 42% 0.58 [0.40-0.85] death 16/34 63/78 Sandhu 53% 0.47 [0.33-0.67] ventilation 16/34 68/68 Sandhu 42% 0.58 [0.40-0.85] no disch. 16/34 63/78 Rodriguez-Nava 6% 0.94 [0.61-1.47] death 16/52 85/261 Tardif (DB RCT) 44% 0.56 [0.19-1.67] death 5/2,235 9/2,253 Tardif (DB RCT) 47% 0.53 [0.25-1.09] ventilation 11/2,235 21/2,253 Tardif (DB RCT) 20% 0.80 [0.61-1.03] hosp. 101/2,235 128/2,253 Recovery C.. (RCT) -1% 1.01 [0.93-1.10] death 1,173/5,610 1,190/5,730 Recovery C.. (RCT) -18% 1.18 [0.99-1.40] ventilation 259/3,815 228/3,962 Recovery C.. (RCT) -2% 1.02 [0.96-1.09] int./death 1,344/5,342 1,343/5,469 Recovery C.. (RCT) -2% 1.02 [0.97-1.06] no disch. 1,709/5,610 1,698/5,730 Gaitán-Dua.. (RCT) 19% 0.81 [0.48-1.35] death 22/153 28/161 CT​1 Gaitán-Dua.. (RCT) 15% 0.85 [0.68-1.06] ventilation 27/136 27/140 CT​1 Gaitán-Dua.. (RCT) 1% 0.99 [0.56-1.74] ICU 19/113 18/114 CT​1 Dorward (RCT) -30% 1.30 [0.42-3.84] hosp./death 6/156 4/133 Dorward (RCT) 22% 0.78 [0.30-1.73] hosp./death 6/156 119/1,145 Dorward (RCT) 6% 0.94 [0.79-1.11] progression 102/156 83/120 Dorward (RCT) 6% 0.94 [0.72-1.24] no recov. 156 (n) 133 (n) Alsultan (RCT) 36% 0.64 [0.20-2.07] death 3/14 7/21 colchicine COVID-19 outcomes c19colchicine.com Jan 18, 2022 1 CT: study uses combined treatment Favors colchicine Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. WCH and FLCCC provide treatment protocols.
  or use drag and drop   
Submit